Apollo Hospitals Q2 growth broadens as capacity expands
Apollo Hospitals reported Q2 revenue growth of 23% and PAT growth of 32% YoY across all three business verticals. OI Charts data showed a 2.7% share-price decline with futures open interest up 2.9%, indicating a short build-up.
pre-market1 source ↓machine-written, see hownot a recommendation
- APOLLOHOSP close
- ₹8,371
- On the day
- -2.66%
- Futures OI, short build-up
- +2.9%
- Put-call ratio
- 0.47
- Max pain
- ₹8,200
Apollo Hospitals reported broader second-quarter growth across its healthcare businesses, with revenue rising 23% year on year and profit after tax increasing 32%. Growth was recorded across all three business verticals, while hospital capacity expansion and improving profitability in digital operations supported the company’s operating outlook. 💊
The update matters because growth is no longer concentrated in a single segment. Additional hospital capacity can increase treatment volumes over time, while stronger digital profitability improves the contribution from the company’s online healthcare operations. However, regulation and one-time costs related to HealthCo remain watchpoints for earnings quality and near-term margins.
Q2 revenue +23% and PAT +32% were accompanied by a negative market reaction on 05 Nov 2026. OI Charts data showed the stock closed at ₹8,371, down 2.7% for the session, on volume of 1,311,349 shares. The broader trend remained positive, with gains of 2.1% over five sessions and 4.8% over 20 sessions. The stock traded between ₹6,696 on 23 Jan 2026 and ₹9,070 on 23 Sep 2026 over the past year.
For derivatives traders, OI Charts data showed futures open interest rising 2.9% to 1,743,200 shares, indicating a short build-up alongside the day’s fall. The futures premium was 0.11%, while the put-call ratio stood at 0.47. The ₹9,000 strike had the largest call open interest and the ₹8,300 strike had the largest put open interest, creating key positioning levels around the current price. Max pain was at ₹8,200 for the 23 Nov 2026 expiry, 18 days away.
The next focus is whether capacity additions and digital profitability continue to offset regulatory pressure and one-time HealthCo costs in subsequent disclosures. Traders will also watch the ₹8,300 put-interest zone and ₹9,000 call-interest ceiling, while the ₹8,200 max-pain level provides a derivatives reference for the November expiry. 🏥
Source: TradingView, 05 Nov 2026
Not investment advice. For informational purposes only.